Nextera: Difference between revisions
Created from NHT member research |
Created with researched data |
||
| Line 1: | Line 1: | ||
{{ | {{DISPLAYTITLE:Nextera}} | ||
|name=Nextera | {{Infobox company | ||
| | | name = Nextera AS | ||
| | | org_number = 994486594 | ||
| | | founded = 2009-08-12 | ||
|funding= | | employees = 9 | ||
| | | address = Oslo Innovation Centre, Gaustadalleen 21, 0349 Oslo | ||
| industry = 72.100 – Biotechnology research | |||
| website = https://www.nextera.no | |||
| nht_category = Startup | |||
| description = Nextera is a drug and target discovery company spun out from University of Oslo and Oslo University Hospital. Developing NextCore platform (pIX phage display) for TCR-Like antibodies targeting pHLA antigens in cancer and autoimmunity. Pipeline includes TCR-Like antibody lead candidates. Received Norwegian Research Council IPN funding November 2025. CEO/CSO Geir Aage Loset. Active at PEGS Europe 2025. | |||
| notes = 9 employees. NRC funding confirmed Nov 2025. Most commercially active biotech in this batch. Presence at PEGS Europe 2025 indicates international visibility. | |||
| related_companies = [[Hemispherian]], [[Exact Therapeutics]], [[Pharmasum Therapeutics]], [[Nordic Brain Tech]], [[Norway Health Tech]] | |||
| categories = Norway Health Tech, Startups, Biotechnology, Drug Discovery, Oncology, Immunology | |||
| sources = https://www.nextera.no; https://data.brreg.no/enhetsregisteret/api/enheter/994486594 | |||
}} | }} | ||
== | == About == | ||
Nextera AS is a Norwegian drug discovery and target discovery company spun out from a Centre of Excellence research environment at the University of Oslo and Oslo University Hospital. The company was founded in 2009. | |||
== | == Technology == | ||
== | === NextCore Platform === | ||
[[Category: | Nextera's proprietary discovery platform combines deep insight into disease mechanisms with unique technology innovation. The platform integrates: | ||
[[Category: | |||
* '''NextCore''' — an integrated platform for developing precision drug candidates targeting the intracellular universe of disease antigens through pHLA (peptide-HLA) | |||
* '''pIX phage display technology''' — core technology enabling discovery of novel antibody candidates | |||
== Pipeline == | |||
The company is developing a pipeline of TCR-Like antibody lead candidates with: | |||
* Exquisite specificity toward disease-specific pHLA targets | |||
* Unique potency for targeted immunotherapy | |||
* Applications in cancer and autoimmunity | |||
== Recent Activity == | |||
* November 2025: Received funding from the Norwegian Research Council through the Innovation Project for the Industrial Sector (IPN) for development of TCR-Like antibodies in autoimmune diseases | |||
* November 2025: Presentation at PEGS Europe 2025 in Lisbon (premier annual protein engineering conference) | |||
* CEO/CSO Geir Aage Loset chairs sessions at PEGS Europe | |||
== Strategy == | |||
Nextera's strategy is to discover new targets and develop cognate drugs together with partners, addressing complex diseases in major indications that are currently difficult to treat. | |||
== References == | |||
<references/> | |||
[[Category:Norway Health Tech]] | |||
[[Category:Startups]] | |||
[[Category:Biotechnology]] | |||
[[Category:Drug Discovery]] | |||
[[Category:Oncology]] | |||
[[Category:Immunology]] | |||
Latest revision as of 20:31, 14 April 2026
About[edit]
Nextera AS is a Norwegian drug discovery and target discovery company spun out from a Centre of Excellence research environment at the University of Oslo and Oslo University Hospital. The company was founded in 2009.
Technology[edit]
NextCore Platform[edit]
Nextera's proprietary discovery platform combines deep insight into disease mechanisms with unique technology innovation. The platform integrates:
- NextCore — an integrated platform for developing precision drug candidates targeting the intracellular universe of disease antigens through pHLA (peptide-HLA)
- pIX phage display technology — core technology enabling discovery of novel antibody candidates
Pipeline[edit]
The company is developing a pipeline of TCR-Like antibody lead candidates with:
- Exquisite specificity toward disease-specific pHLA targets
- Unique potency for targeted immunotherapy
- Applications in cancer and autoimmunity
Recent Activity[edit]
- November 2025: Received funding from the Norwegian Research Council through the Innovation Project for the Industrial Sector (IPN) for development of TCR-Like antibodies in autoimmune diseases
- November 2025: Presentation at PEGS Europe 2025 in Lisbon (premier annual protein engineering conference)
- CEO/CSO Geir Aage Loset chairs sessions at PEGS Europe
Strategy[edit]
Nextera's strategy is to discover new targets and develop cognate drugs together with partners, addressing complex diseases in major indications that are currently difficult to treat.